International Journal of Drug Delivery Technology
Volume 14, Issue 3

Promising Drug Delivery System for Cervical Cancer – A Future Approach

Gayatri S Ahir, Rahul G Ingle*

Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (DMIHER), Deemed to be University, Wardha, Maharashtra, India. 

Received: 27th July, 2024; Revised: 10th August, 2024; Accepted: 19th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

There is evidence that peptide targeting can be applied in cervical cancer therapy and for diagnosis involving the use of molecular imaging, hence developing peptide probes for this disease. Cervical cancer, which also has a high possibility of being prevented, is among the common tumors affecting women globally. Despite the occurrence being reduced greatly by screening, the illness remains fatal and its claims many lives annually, especially in the developing nations. In exercising such a perspective, specific public health efforts known to encourage physical activity, proper diet, and early detection of cervical cancer must begin to be taken seriously. When combined, doctors, health officers, and lawmakers could speed up the global deployment of such programs. California’s American Cancer Society, the present review enlists a host of pharmaceutical goods available in the market. This perspective of present-day research and manufacturing is devoted to the development of various types of nanocarriers for possible utilization in medication transport. Thus, overall cancer mortality appears to be not substantially different, though cancer incidence rates for both sexes are 50% lower in impoverished countries when compared to affluent nations. At the moment, there are new peptide probes that are developed solely for cervical cancer-perfectly suitable for targeting peptides applicable in therapeutic and diagnostic imaging. M13KE phage dodecapeptide (12-mer) peptide library was screened for recognition of human immunodeficiency virus type 1 (HIV-1) by immunofluorescence and flow cytometry; the S7 clone was identified as most suitable. A disease that affects many women is gynecologic health problems, and cervical cancer is the leading presenting complaint experienced regularly. Among these studies, QSAR, drug-likeness, PCA, dynamic cross-correlation matrix, molecular docking, molecular dynamics and quantum calculation properties can be listed. In the first literature survey, after identifying the potent antibacterial and anticancer activity of the molecule apigenin, some other promising derivatives were identified and more research has been carried out on them, focusing on their synthesized derivatives as inhibitors of DNA polymerase theta and cervical cancer caused by human papillomavirus. The results were streamlined by the use of in-silico molecular docking, which showed that all Apigenin derivatives and the targeted proteins had potential energy-binding relationships. Further validation is essential because this study used in-silico computational methodologies and produced excellent results. Applying in-silico molecular docking made the data more comprehensible, which showed the possible energy bindings of the targeted proteins and all the Apigenin variants. Due to the fact that this work utilized in-silico computational methods and obtained significant results, further validation is required. Hence, the present wet-lab experiments coupled with both in-vitro and in-vivo conditions, additional validation of the results.

Keywords: Cervical cancer, Antisense lncRNA, Magnetic thermosensitive cationic liposome, Oxaliplatin. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.75

How to cite this article: Ahir GS, Ingle RG. Promising Drug Delivery System for Cervical Cancer – A Future Approach. International Journal of Drug Delivery Technology. 2024;14(3):1785-1790.

REFERENCES

  1. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The 2019; 393(10167):169-182. https://doi.org/10.1016/ S0140-6736(18)32470-X
  2. Akash S, Bayıl I, Hossain MS, Islam MR, Hosen ME, Mekonnen AB, Nafidi HA, Bin Jardan YA, Bourhia M, Bin Emran Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives. Scientific Reports. 2023; 13(1):16565. https://doi.org/10.1038/s41598-023-43175-x
  3. Krakauer EL, Kwete X, Kane K, Afshan G, Bazzett-Matabele L, Bien-Aimé DD, Byrne-Martelli S, Connor S, Correa R, Devi CB, Diop M. Cervical cancer-associated suffering: estimating the palliative care needs of a highly vulnerable population. JCO Global Oncology. 2021; 7:862-872. https://doi.org/10.1200/ GO.21.00025
  4. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational oncology. 2021; 14(10):101174. https://doi.org/10.1016/j.tranon.2021.101174
  5. Wu X, Qiu L, Lou W, Wang X, Zhu T, Zhang Y, Hu W, Xue X, Zhu Z, Xiang L, Li A multicenter non-inferior randomizedcontrolled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stages IB1, IB2, and IIA1): study protocol of the LAUNCH 2 trial. Trials. 2022; 23(1):269. https://doi.org/10.1186/s13063-022-06245-5
  6. Moleyar-Narayana P, Leslie S, Ranganathan Cancer screening. StatPearls. 2024.
  7. Cho CJ, Brown JW, Mills JC. Origins of cancer: ain’t it just mature cells misbehaving? The EMBO Journal. 2024:1-22. https://doi.org/10.1038/s44318-024-00099-0
  8. Obaid AL-Mawla1 BS, Khalil MA, Murshid RM, Ameen BA. Prevalence and Genotype Distribution of Cervical High-Risk Human Papilloma Virus in Cervical Specimens of Woman with Normal and Abnormal Cytology in Anbar province, Iraq. International Journal of Drug Delivery 2021;11(1):1-; DOI: 10.25258/ijddt.11.1.1
  9. Katare KK, Mandapati U, Seelam M, Gundumolu SR, VedulaDevelopment and Validation of RP-HPLC Method for the Simultaneous Determination of Cisplatin, Capecitabine and Trastuzumab. International Journal of Pharmaceutical Quality Assurance. 2022;13(1):30-38. DOI: 10.25258/ijpqa.13.1.8
  10. Ke Z, Xu Y, Shu Y, Wang C, Wu B, Zhang B, Xiang P, Hu X. Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer. Translational Cancer Research. 2024; 13(2):676. https://doi. org/10.21037%2Ftcr-23-1680
  11. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):475-480. DOI: 10.25258/ijpqa.14.3.03
  12. Alubaidi GT. Virus-like Particles-Application in Nano Vaccines: A Review. International Journal of Drug Delivery Technology. 2020;10(3):366-368. DOI: 10.25258/ijddt.10.3.10
  13. World Health Considerations for human papillomavirus (HPV) vaccine product choice. World Health Organization; 2024.